NCT07294508 2025-12-29A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerShanghai Henlius BiotechPhase 2/3 Not yet recruiting706 enrolled
NCT07294534 2025-12-19A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat CancerShanghai Henlius BiotechPhase 2/3 Not yet recruiting817 enrolled